# Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

> **NCT04629443** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 17 (actual)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** S 64315 (also referred as MIK665) and azacitidine

## Key facts

- **NCT ID:** NCT04629443
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-08-25
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629443, "Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04629443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*